FIGO staging for gestational trophoblastic neoplasia: 2026

International Journal of Gynecology & Obstetrics 2026 Open access

Read full text
Authors: Hextan YS NGAN, Seckl Mj, Neil Horowitz, Annie N. Y. Cheung, Antonio Braga, Paradan K. Sekharan, Susanne Fridsten, Andrea Garrett, Nozomu Yanaihara, Sarikapan Wilailak, Barbara Schmalfeldt
DOI: 10.1002/ijgo.71229
Cited by: 1
References: 22

Abstract

Gestational trophoblastic neoplasia (GTN) encompasses a wide range of diseases, which include choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor, and post-molar persistent or rising levels of human chorionic gonadotrophin. Standardization of the diagnostic criteria and investigative approaches for this uncommon, potentially lethal, yet highly treatable disease is important. Adoption of an evidence-based staging and scoring system is essential to guide patient management and enable comparison of treatment outcomes. An updated staging system for GTN has been proposed and adopted by the Committee on Women's Cancer of the International Federation of Gynecology and Obstetrics (FIGO) for this purpose. This article highlights the changes introduced in the 2026 system and provide explanatory notes to facilitate interpretation.

Fields of Study & Subjects

Gestational Trophoblastic Disease Studies Maternal and fetal healthcare Pregnancy and preeclampsia studies

Publication details

Journal / source
International Journal of Gynecology & Obstetrics
Publisher
Wiley
Volume
174
Issue
3
Pages
1172–1180
Publication date
19 July 2026
Language
EN